Cullinan Therapeutics Inc.
Clinical trials sponsored by Cullinan Therapeutics Inc., explained in plain language.
A clinical-stage biopharmaceutical company developing targeted cancer therapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New antibody takes on Hard-to-Treat myeloma Results expected Sep 2026 (estimated)
- New lupus drug CLN-978 enters early human testing Results expected Dec 2026 (estimated)
- New drug CLN-049 aims to fight Hard-to-Treat blood cancers Results expected Jan 2027 (estimated)
-
Can a bispecific antibody tame two autoimmune blood disorders?
Disease control Not yet recruitingThis trial is testing an investigational drug called velinotamig in adults with immune thrombocytopenia (ITP) or warm autoimmune hemolytic anemia (wAIHA) that has relapsed or not responded to standard treatments. Velinotamig is an engineered bispecific antibody designed to target…
Phase 1/2 • Sponsor: Cullinan Therapeutics Inc. • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Can a triple-drug combination tame AML without intensive chemo?
Disease control Not yet recruitingThis trial tests whether adding an experimental drug called CLN 049 to two standard AML drugs (azacitidine and venetoclax) is safe and tolerable for adults newly diagnosed with acute myeloid leukemia who are not candidates for intensive chemotherapy. The study will first find the…
Phase 1 • Sponsor: Cullinan Therapeutics Inc. • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC